

IN THE ABSTRACT

No changes.

IN THE DISCLOSURE

No changes.

IN THE CLAIMS

BB1
11. (Twice Amended) The method of Claim 9 wherein the amount of the hyaluronic acid or salt thereof is in excess of [5-6] 50-60 mg per dosage and has a molecular weight less than about 750,000 daltons.

BB2
15. (Twice Amended) The method of Claim 13 wherein the amount of the hyaluronic acid or salt thereof is in excess of [5-6] 50-60 mg per dosage and has a molecular weight less than about 750,000 daltons.

BB3
20. (Twice Amended) The delivery of Claim 18 wherein the amount of the hyaluronic acid or salt thereof is in excess of [5-6] 50-60 mg per dosage and has a molecular weight less than about 750,000 daltons.

REMARKS

The Examiner will note that claims 11, 15 and 20 have been amended to delete 5-6 mg and insert 50-60 mg. When Applicants' agent performed the calculations on the dosage amounts taught in the application (for example at page 50, lines 12,19) , when 2 gm dosage amounts were administered, the constituents were 2 1/2 - 3% of the form of hyaluronic acid. The dosage amount is therefore 50-60 mg of the form of hyaluronic acid (sodium hyaluronate) not 5-6 mg. This is an error on the part of Applicants' agent, is apparent from the teachings of the application and is now being corrected. No new subject matter has been added to the application.

In the latest Official Action, the Office has indicated that the previous restriction made by the Patent office is withdrawn. The Patent Office therefore provided two new groups of claims, Groups I and II. Group I the Office asserts are drawn to a pharmaceutical